CoChat

Peroxisomal alterations in Alzheimer’s disease

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

In Alzheimer's disease (AD), lipid alterations are present early during disease progression. As some of these alterations point towards a peroxisomal dysfunction, we investigated peroxisomes in human postmortem brains obtained from the cohort-based, longitudinal Vienna-Transdanube Aging (VITA) study. Based on the neuropathological Braak staging for AD on one hemisphere, the patients were grouped into three cohorts of increasing severity (stages I-II, III-IV, and V-VI, respectively). Lipid analyses of cortical regions from the other hemisphere revealed accumulation of C22:0 and very long-chain fatty acids (VLCFA, C24:0 and C26:0), all substrates for peroxisomal β-oxidation, in cases with stages V-VI pathology compared with those modestly affected (stages I-II). Conversely, the level of plasmalogens, which need intact peroxisomes for their biosynthesis, was decreased in severely affected tissues, in agreement with a peroxisomal dysfunction. In addition, the peroxisomal volume density was increased in the soma of neurons in gyrus frontalis at advanced AD stages. Confocal laser microscopy demonstrated a loss of peroxisomes in neuronal processes with abnormally phosphorylated tau protein, implicating impaired trafficking as the cause of altered peroxisomal distribution. Besides the original Braak staging, the study design allowed a direct correlation between the biochemical findings and the amount of neurofibrillary tangles (NFT) and neuritic plaques, quantified in adjacent tissue sections. Interestingly, the decrease in plasmalogens and the increase in VLCFA and peroxisomal volume density in neuronal somata all showed a stronger association with NFT than with neuritic plaques. These results indicate substantial peroxisome-related alterations in AD, which may contribute to the progression of AD pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00401-011-0836-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Accumulation of VLCFA in cortical areas of human brains associated with progressive AD neuropathology. a The content of long and very long-chain fatty acids in five different cortical regions, indicated below the graphs, was determined by GC–MS (n = 10/group). Relative amounts of the fatty acids C16:0, C18:0, C22:0, C24:0 and C26:0 are depicted as ratio to the total fatty acid (TFA) content (×1,000). The mean values of each AD severity group are connected across brain regions by the line pattern indicated above the graphs. The AD-related neuropathology was defined according to Braak staging of the contralateral hemisphere. Tissue abbreviations: PS parasubiculum, TEC trans-entorhinal cortex, GF gyrus frontalis, GP gyrus precentralis, CB cerebellar cortex. The mean level of VLCFA (C24:0 and C26:0 combined) in gyrus frontalis is depicted as ratio to total fatty acids for the three Braak stage groups (b) and of C22:0 (c) and VLCFA (d) in relation to NFT and plaques. The increase in VLCFA in stage V–VI when compared with stage I–II was statistically significant (corr. p = 0.044). When NFT were present, both C22:0 (c left) and VLCFA (d left) were significantly increased (p = 0.013 and 0.003, respectively). Also when the cases were grouped according to plaques, the levels of C22:0 (c right) and VLCFA (d right) were elevated when plaques were present, but to a lesser extent (p = 0.030 and 0.165, respectively). Thus, the increase in VLCFA was more strongly associated with NFT than with plaques. Error bars indicate SEM; *p < 0.05 and **p < 0.01; corr., corrected for multiple testing (Tukey’s post hoc test)
Fig. 1 Accumulation of VLCFA in cortical areas of human brains associated with progressive AD neuropathology. a The content of long and very long-chain fatty acids in five different cortical regions, indicated below the graphs, was determined by GC–MS (n = 10/group). Relative amounts of the fatty acids C16:0, C18:0, C22:0, C24:0 and C26:0 are depicted as ratio to the total fatty acid (TFA) content (×1,000). The mean values of each AD severity group are connected across brain regions by the line pattern indicated above the graphs. The AD-related neuropathology was defined according to Braak staging of the contralateral hemisphere. Tissue abbreviations: PS parasubiculum, TEC trans-entorhinal cortex, GF gyrus frontalis, GP gyrus precentralis, CB cerebellar cortex. The mean level of VLCFA (C24:0 and C26:0 combined) in gyrus frontalis is depicted as ratio to total fatty acids for the three Braak stage groups (b) and of C22:0 (c) and VLCFA (d) in relation to NFT and plaques. The increase in VLCFA in stage V–VI when compared with stage I–II was statistically significant (corr. p = 0.044). When NFT were present, both C22:0 (c left) and VLCFA (d left) were significantly increased (p = 0.013 and 0.003, respectively). Also when the cases were grouped according to plaques, the levels of C22:0 (c right) and VLCFA (d right) were elevated when plaques were present, but to a lesser extent (p = 0.030 and 0.165, respectively). Thus, the increase in VLCFA was more strongly associated with NFT than with plaques. Error bars indicate SEM; *p < 0.05 and **p < 0.01; corr., corrected for multiple testing (Tukey’s post hoc test)CC BY-NC · PubMed Central
Fig. 2 Plasmalogens are reduced in gyrus frontalis with AD pathology. a Schematic structure of plasmalogen. b, c The relative levels of total ethanolamine plasmalogens (PlsEtn) in gyrus frontalis medius were determined by GC–MS and expressed as ratio to the total fatty acid (TFA) content (×1,000). Reduced levels were observed when the samples were grouped either by Braak staging of neuropathology (b corr. p = 0.027) or by the presence or absence of NFT (c left; p = 0.004) or plaques (c right; p = 0.300). d Individual plasmalogen sub-species were determined by nano-ESI–MS and depicted as percentage of the mean level of the same plasmalogen species in samples without NFT. The four main species (striped) account together for 58.5% of total plasmalogen. e The level of plasmalogen species grouped according to the degree of saturation of the fatty acid at the sn-2 position and the presence or absence of NFT. The difference between the 6.1% increase in plasmalogens with saturated (sat) or monounsaturated (MUFA) fatty acids at sn-2 compared with the 7.7% decrease in those with polyunsaturated fatty acids (PUFA) is statistically significant (p = 0.019) The number (n) of cases in each group are indicated below the graphs. Error bars indicate SEM; *p < 0.05 and **p < 0.01; corr., corrected for multiple testing (Tukey’s post hoc test)
Fig. 2 Plasmalogens are reduced in gyrus frontalis with AD pathology. a Schematic structure of plasmalogen. b, c The relative levels of total ethanolamine plasmalogens (PlsEtn) in gyrus frontalis medius were determined by GC–MS and expressed as ratio to the total fatty acid (TFA) content (×1,000). Reduced levels were observed when the samples were grouped either by Braak staging of neuropathology (b corr. p = 0.027) or by the presence or absence of NFT (c left; p = 0.004) or plaques (c right; p = 0.300). d Individual plasmalogen sub-species were determined by nano-ESI–MS and depicted as percentage of the mean level of the same plasmalogen species in samples without NFT. The four main species (striped) account together for 58.5% of total plasmalogen. e The level of plasmalogen species grouped according to the degree of saturation of the fatty acid at the sn-2 position and the presence or absence of NFT. The difference between the 6.1% increase in plasmalogens with saturated (sat) or monounsaturated (MUFA) fatty acids at sn-2 compared with the 7.7% decrease in those with polyunsaturated fatty acids (PUFA) is statistically significant (p = 0.019) The number (n) of cases in each group are indicated below the graphs. Error bars indicate SEM; *p < 0.05 and **p < 0.01; corr., corrected for multiple testing (Tukey’s post hoc test)CC BY-NC · PubMed Central
Fig. 3 Increased peroxisome density in the soma of neurons in gyrus frontalis is associated with NFT. a The peroxisome density in the cell body of at least 24 neurons (each represented by a circle) in gyrus frontalis from each of the 30 cases in the cohort was determined by morphometry after immunohistochemical staining for PMP70 and plotted as pixel/mm2. The total number of analyzed neurons/Braak group is indicated at the bottom of the panel. b The increase in mean peroxisome volume density was statistically significant in tissues containing NFT (p = 0.018) but not in the group with plaques only (p = 0.123). The observation that the increase was more strongly associated with NFT than with plaques was statistically significant (p = 0.001). The number (n) of cases in each group is indicated below the graphs. Error bars indicate SEM; *p < 0.05
Fig. 3 Increased peroxisome density in the soma of neurons in gyrus frontalis is associated with NFT. a The peroxisome density in the cell body of at least 24 neurons (each represented by a circle) in gyrus frontalis from each of the 30 cases in the cohort was determined by morphometry after immunohistochemical staining for PMP70 and plotted as pixel/mm2. The total number of analyzed neurons/Braak group is indicated at the bottom of the panel. b The increase in mean peroxisome volume density was statistically significant in tissues containing NFT (p = 0.018) but not in the group with plaques only (p = 0.123). The observation that the increase was more strongly associated with NFT than with plaques was statistically significant (p = 0.001). The number (n) of cases in each group is indicated below the graphs. Error bars indicate SEM; *p < 0.05CC BY-NC · PubMed Central
Fig. 4 Peroxisomes but not mitochondria are absent from neuronal processes featuring pre-tangles. Representative images of confocal double-immunofluorescence using AT8 antibody to detect phospho-tau (pre-tangle marker) and either PMP70-positive peroxisomes (a, c, e) or SOD2-positive mitochondria (b, d, f) in entorhinal cortex of an AD patient with Braak stage IV. a , b In the absence of phosphorylated tau, numerous peroxisomes (a) and mitochondria (b) are present in the neuronal processes. When phosphorylated tau is present, peroxisomes are only visible in the soma (arrow), but not in the neuronal process (c arrowheads pointing upwards), but normal amounts of mitochondria are present (d). Note the abundance of peroxisomes in a neighboring neuron, in which no phospho-tau is detected (c arrowheads pointing downwards). e, f In neurons filled with NFT, no peroxisomes and only sporadic mitochondria were detected in the soma. Size bar 10 μm
Fig. 4 Peroxisomes but not mitochondria are absent from neuronal processes featuring pre-tangles. Representative images of confocal double-immunofluorescence using AT8 antibody to detect phospho-tau (pre-tangle marker) and either PMP70-positive peroxisomes (a, c, e) or SOD2-positive mitochondria (b, d, f) in entorhinal cortex of an AD patient with Braak stage IV. a , b In the absence of phosphorylated tau, numerous peroxisomes (a) and mitochondria (b) are present in the neuronal processes. When phosphorylated tau is present, peroxisomes are only visible in the soma (arrow), but not in the neuronal process (c arrowheads pointing upwards), but normal amounts of mitochondria are present (d). Note the abundance of peroxisomes in a neighboring neuron, in which no phospho-tau is detected (c arrowheads pointing downwards). e, f In neurons filled with NFT, no peroxisomes and only sporadic mitochondria were detected in the soma. Size bar 10 μmCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 228

Metadata

Authors
Kou, J., Kovacs, G. G., Höftberger, R., Kulik, W., Brodde, A., Forss-Petter, S., Hönigschnabl, S., Gleiss, A., Brügger, B., Wanders, R., Just, W., Budka, H., Jungwirth, S., Fischer, P., & Berger, J.
Affiliations
  • Medical University of Vienna (AT)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Heidelberg University (DE)
  • Ludwig Boltzmann Institute for Age Research (AT)
Corresponding author
Berger, Johannes
Venue
Acta Neuropathologica
Published
2011-05-19
Volume
122
Issue
3
Pages
271-283
ISSN
  • 0001-6322 (ISSN-L)
  • 1432-0533
OpenAlex
W2124956869
Cited by
227
References
42
Citations by year
2026: 7 · 2025: 21 · 2024: 12 · 2023: 20 · 2022: 22 · 2021: 17 · 2020: 25 · 2019: 13 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 17 · 2014: 19 · 2013: 10 · 2012: 12
FWCI
9.16
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Acta Neuropathologica (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Funders
  • European Commission (LSHG-CT-2004-512018)
  • Austrian Science Fund (P 21950)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
Alzheimer's disease, peroxisomes, peroxisomal dysfunction, very long chain fatty acids, plasmalogens, peroxisomal beta-oxidation, neurofibrillary tangles, neuritic plaques, Braak staging, tau phosphorylation, neuronal soma
MeSH terms
Aged, 80 and over, Alzheimer Disease, Brain, Double-Blind Method, Fatty Acids, Female, Humans, Male, Myelin Sheath, Plasmalogens, Postmortem Changes, Cohort Studies, Neurofibrillary Tangles, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.